UMRX Unum Therapeutics Inc.

0.69
+0.02  (+2%)
Previous Close 0.67
Open 0.68
Price To Book 0.74
Market Cap 21,053,253
Shares 30,663,054
Volume 384,694
Short Ratio
Av. Daily Volume 206,199
Stock charts supplied by TradingView

NewsSee all news

  1. Unum Therapeutics to Present at Upcoming Investor Conference

    CAMBRIDGE, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ:UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced its

  2. Unum Therapeutics Reports Third Quarter 2019 Financial Results

    - Progress towards focusing on solid tumors remains on track with enrollment and early safety updates from Phase 1 trial of ACTR707 in HER2+ cancers expected by the end of this year- CAMBRIDGE, Mass., Nov. 12, 2019

  3. Unum Therapeutics Presents Preclinical Data for BOXR1030 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

    - Unum's first product candidate from its BOXR platform, BOXR1030, is designed to improve T cell functionality in the solid tumor microenvironment -           - BOXR1030 T cells co-express the GOT2 transgene to improve

  4. Unum Therapeutics Announces Strategic Focus on Developing Best-in-Class Cellular Therapies for Solid Tumor Cancers

    - Solid tumor cancers represent the greatest unmet medical need for targeted cell therapies; Unum's goals are to more selectively target solid tumors with its ACTR platform candidates and improve T cell functionality in

  5. Unum Therapeutics Announces Data Presentation at the Upcoming Society for Immunotherapy of Cancer (SITC) Meeting

    CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ:UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced acceptance

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1 dose escalation suspended - noted November 4, 2019.
ACTR087 + SEA-BCMA (ATTCK-17-01)
Multiple Myeloma
Phase 1 presentation at ASH December 7, 2019, 5:30 p.m. ET.
ACTR707 + rituximab (ATTCK-20-03)
CD20+ Non-Hodgkin Lymphoma (NHL)
Phase 1 trial placed on clinical hold - July 2, 2019. Data to be presented at ASH December 7, 2019: 2:45 PM.
ACTR087 + rituximab (ATTCK-20-2)
Non-Hodgkin Lymphoma (NHL)
Phase 1 safety and clinical response data due 2020.
ACTR T cells (ATTCK-34-01)
Solid tumors

Latest News

  1. Unum Therapeutics to Present at Upcoming Investor Conference

    CAMBRIDGE, Mass., Nov. 15, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ:UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced its

  2. Unum Therapeutics Reports Third Quarter 2019 Financial Results

    - Progress towards focusing on solid tumors remains on track with enrollment and early safety updates from Phase 1 trial of ACTR707 in HER2+ cancers expected by the end of this year- CAMBRIDGE, Mass., Nov. 12, 2019

  3. Unum Therapeutics Presents Preclinical Data for BOXR1030 at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

    - Unum's first product candidate from its BOXR platform, BOXR1030, is designed to improve T cell functionality in the solid tumor microenvironment -           - BOXR1030 T cells co-express the GOT2 transgene to improve

  4. Unum Therapeutics Announces Strategic Focus on Developing Best-in-Class Cellular Therapies for Solid Tumor Cancers

    - Solid tumor cancers represent the greatest unmet medical need for targeted cell therapies; Unum's goals are to more selectively target solid tumors with its ACTR platform candidates and improve T cell functionality in

  5. Unum Therapeutics Announces Data Presentation at the Upcoming Society for Immunotherapy of Cancer (SITC) Meeting

    CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ:UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced acceptance

  6. Unum Therapeutics to Present at Upcoming Industry Conferences in September

    CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ:UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced its

  7. Unum Therapeutics to Present at Upcoming September Investor Conferences

    CAMBRIDGE, Mass., Aug. 26, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ:UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced that